{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 45,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Slide 25 of a conference presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/25",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.32,
        "x": 0.65,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Sustained C5 leadership with durable Ultomiris and Soliris growth",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93ab759c-de64-49e0-81f5-84af57533a55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.66,
        "w": 0.33,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Rare Disease Revenue by Product",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd130f00-acea-4428-8808-4533731c8dc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.32,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Ultomiris and Soliris Conversion",
      "attrs": null,
      "subkind": "bar-stacked-100pct",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b850d427-7374-44bf-a9ae-e85b3eda62eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.37,
        "y": 0.23
      },
      "kind": "list",
      "text": "Q4 2023: key dynamics: Sustainable, durable growth of C5 Franchise; Ultomiris, +38% driven by neurology expansion; Soliris, (13%) due to conversion, partly offset by Emerging Markets growth",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ccafb02-bab1-42a4-96b2-5976e4c61ce4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.26,
        "x": 0.37,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "Strensiq, +13% and Koselugo, +48% driven by continued patient demand",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a798388-43b2-49e5-8ffc-2df2e801fa79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "All growth rates at CER. 1. Patients converting their treatment from Soliris to Ultomiris 2. Includes Kanuma and Koselugo. 25 Collaboration partners: Merck & Co., Inc. (Koselugo). Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28a49bde-e36d-44bb-b5bf-3f2ef514124d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Total Revenue +12% in FY 2023 driven by neurology and patient demand",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "279ab01d-14fd-42f0-aeca-9775b7882293",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Rare Disease – FY and Q4 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f4c041f-34c4-4c81-9043-cef935c6550d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "896cafa4-9b70-4151-be72-5b70996c6599",
      "evidence": "list/bullet: Q4 2023: key dynamics: Sustainable, durable growth of C5 Franchise; Ultomiris, +38% driven by neurology expansion; Soliris, (13%) due to conversion, partly offset by Emerging Markets growth",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "43aa94ba-8d07-4798-99cd-6d40ae4b13e2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides an overview of AstraZeneca's financial results and pipeline success",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}